IP Verse

Immediate Release Tablet Formulations - EP2498759

The patent EP2498759 was granted to Astrazeneca on Aug 1, 2018. The application was originally filed on Nov 12, 2010 under application number EP10782116A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP2498759

ASTRAZENECA
Application Number
EP10782116A
Filing Date
Nov 12, 2010
Status
Granted And Under Opposition
Jun 29, 2018
Grant Date
Aug 1, 2018
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (4)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GALENICUM HEALTH SLUMay 2, 2019GALENICUM HEALTH SLUADMISSIBLE
GENERICS UKApr 30, 2019TER MEER STEINMEISTER & PARTNERADMISSIBLE
HOEFER & PARTNER PATENTANWALTE MBBApr 30, 2019-ADMISSIBLE
STADA ARZNEIMITTELApr 30, 2019KERNEBECKADMISSIBLE

Patent Citations (109) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS19990391053-
DESCRIPTIONUS20040899641-
DESCRIPTIONEP0142146
DESCRIPTIONEP0221025
DESCRIPTIONEP2009010
DESCRIPTIONFR2596393
DESCRIPTIONGB2205837
DESCRIPTIONUS2007197623
DESCRIPTIONUS2009030198
DESCRIPTIONUS3674836
DESCRIPTIONUS3983140
DESCRIPTIONUS4027009
DESCRIPTIONUS4231938
DESCRIPTIONUS4346227
DESCRIPTIONUS4448784
DESCRIPTIONUS4450171
DESCRIPTIONUS4499289
DESCRIPTIONUS4613610
DESCRIPTIONUS4647576
DESCRIPTIONUS4681893
DESCRIPTIONUS4686237
DESCRIPTIONUS4759923
DESCRIPTIONUS4871721
DESCRIPTIONUS4924024
DESCRIPTIONUS5006530
DESCRIPTIONUS5011930
DESCRIPTIONUS5177080
DESCRIPTIONUS5260440
DESCRIPTIONUS5273995
DESCRIPTIONUS5354772
DESCRIPTIONUS5385929
DESCRIPTIONUS5488064
DESCRIPTIONUS5491134
DESCRIPTIONUS5506219
DESCRIPTIONUS5541204
DESCRIPTIONUS5594016
DESCRIPTIONUS5595872
DESCRIPTIONUS5612359
DESCRIPTIONUS5614492
DESCRIPTIONUS5686104
DESCRIPTIONUS5691322
DESCRIPTIONUS5712279
DESCRIPTIONUS5712396
DESCRIPTIONUS5739135
DESCRIPTIONUS5753675
DESCRIPTIONUS5760246
DESCRIPTIONUS5770615
DESCRIPTIONUS5776983
DESCRIPTIONUS5827875
DESCRIPTIONUS5885983
DESCRIPTIONUS5962440
DESCRIPTIONUS6043265
DESCRIPTIONUS6395767
DESCRIPTIONUS6414002
DESCRIPTIONUS6414126
DESCRIPTIONUS6515117
DESCRIPTIONUS6548529
DESCRIPTIONUS6653314
DESCRIPTIONUS7288528
DESCRIPTIONUS7589193
DESCRIPTIONWO0001389
DESCRIPTIONWO0039077
DESCRIPTIONWO0121602
DESCRIPTIONWO03033671
DESCRIPTIONWO03099836
DESCRIPTIONWO2005117841
DESCRIPTIONWO2007007628
DESCRIPTIONWO2008002824
DESCRIPTIONWO2008116179
DESCRIPTIONWO2009003596
DESCRIPTIONWO8603488
DESCRIPTIONWO8607054
DESCRIPTIONWO9638144
DESCRIPTIONWO9712613
DESCRIPTIONWO9712615
DESCRIPTIONWO9721993
DESCRIPTIONWO9900353
DESCRIPTIONWO9938501
DESCRIPTIONWO9946272
DESCRIPTIONWO9961431
DESCRIPTIONWO9967278
DESCRIPTIONWO9967279
INTERNATIONAL-SEARCH-REPORTWO2005117841
INTERNATIONAL-SEARCH-REPORTWO2008116179
INTERNATIONAL-SEARCH-REPORTWO2010045656
OPPOSITIONEP2498759
OPPOSITIONJP2002326927
OPPOSITIONUS2005266080
OPPOSITIONUS2006057202
OPPOSITIONUS2008234366
OPPOSITIONUS7589193
OPPOSITIONWO03066028
OPPOSITIONWO2005065663
OPPOSITIONWO2005117841
OPPOSITIONWO2007078726
OPPOSITIONWO2007131930
OPPOSITIONWO2008050987
OPPOSITIONWO2008055940
OPPOSITIONWO2008113000
OPPOSITIONWO2008116179
OPPOSITIONWO2009011451
OPPOSITIONWO2009099734
OPPOSITIONWO2009111200
OPPOSITIONWO2009121945
OPPOSITIONWO2009143021
OPPOSITIONWO2010045656
OPPOSITIONWO2010138535
OPPOSITIONWO2011006029
OPPOSITIONWO2011039337

Non-Patent Literature (NPL) Citations (36) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- (20091026), URL: https://clinicaltrials.govict2/history/NCTO1002807?V_1=View#StudyPageTop, XP002663638-
OPPOSITION- "6.2.3. Process Related Variables", Parikh M Dilip, Handbook of Pharmaceutical Granulation Technology, (20050000), pages 269,274 - 277, XP055591597-
OPPOSITION- "ACTOPLUS METâ„¢ (pioglitazone hydrochloride and metformin hydrochloride tablets)", (20060800), page 27pp, XP055591742-
OPPOSITION- "Annex 5 Guidelines for registration of fixed-dose combination medicinal products", WHO Technical Report Series No. 929, (20050000), page 94, 112, XP055591673-
OPPOSITION- Anonymous, "Archive History for NCT00528879", clinicaltrials, (20090903), URL: https://clinicaltrials.gov/ct2/history/NCT00528879?V_39=View#StudyPageTop, XP055588764-
OPPOSITION- "Assessment Report for Janumet (EMEA/H/C/000861)", EMEA, (20080000), pages 1 - 43, XP055591802-
OPPOSITION- "bandelin A. Fillers", Pharmaceutical dosage forms: tablets, (19890000), vol. 1, pages 152 - 153, XP055591650-
OPPOSITION- "Bandelin B. Binders", Lieberman et al., Pharmaceutical dosage forms: tablets, (19890000), vol. 1, page 160, XP055591642-
OPPOSITION- Bristol-Myers Squibb, "MetaglipTM (glipizide and metformin HCI) Tablets 2.5 mg/250 mg 2.5 mg/500 mg 5 . mg/500 mg", (20070618), pages 1 - 33, URL: https://www.accessdata.fda.qov/scripts/cder/daf/index.cfm?event=overview.proce ss&AppINo=021460, XP055591740-
OPPOSITION- "Cellulose, Microcrystalline", Handbook of Pharmaceutical Excipients, (20060000), pages 132 - 135, XP002483911-
OPPOSITION- C. J. BAILEY et al., "Dapagliflozin as an add- on to metformin lowers hyperglycaemia in type 2 diabetes patients inadequately controlled with metformin alone; abstract 169 of oral presentation 29 Novel therapies for type 2 diabetes mellitus at the 45th EASD Annual Meeting of the European Association for the Study of Diab", Diabetologia, Vienna, Austria, (20090000), vol. 52, page S76-
OPPOSITION- "Compressed Tablets by Wet Granulation C. Lubricants", Pharmaceutical dosage forms: tablets, (19890000), vol. 1, page 169, XP055591661-
OPPOSITION- "Compressed Tablets by Wet Granulation D. Disintegrants", Pharmaceutical dosage forms: tablets volume 1, (19890000), vol. 1, pages 173 - 177, XP055591670-
OPPOSITION- GlaxoSmithKline, "AvandametTM brand of rosiglitazone maleate and metformin hydrochloride tablets", (20030410), pages 3 - 22, XP055591704-
OPPOSITION- "GLUCOVANCE® (Glyburide and Metformin HCI Tablets)1.25 mg/250 mg 2.5 mg/500 mg 5 mg/500 mg", (20060930), page 32pp, XP055591676-
OPPOSITION- Handbook of Pharmaceutical Excipients, Sixth ed., (20090205), pages 129 - 133-
OPPOSITION- "Hydroxypropyl Cellulose", Handbook of Pharmaceutical Excipients, (20060000), pages 336 - 340, XP008167868-
OPPOSITION- "Hydroxypropyl Cellulose, Low-substituted", Handbook of Pharmaceutical Excipients, (20060000), pages 341 - 343, XP002547079-
OPPOSITION- JACK ZHENG, FORMULATION AND ANALYTICAL DEVELOPMENT FOR LOW-DOSE ORAL DRUG PRODUCTS, (20090000), page 63,77-78,86-
OPPOSITION- "Janumet (sitagliptin and metformin HCI)", (20080100), pages 1 - 22, XP055591796-
OPPOSITION- J. CALADO, "Dapagliflozin, an oral sodium glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus", IDrugs, (20090000), vol. 12, no. 12, pages 785 - 798, XP009136677-
OPPOSITION- "Magnesium Stearate", Handbook of Pharmaceutical Excipients, (20050000), pages 430 - 433, XP055591638-
OPPOSITION- "Mixing and formulation of low dose drugs: underlying problems and solutions", Thai J. Pharm. Sci., (20080000), vol. 32, pages 43 - 58, XP055012249-
OPPOSITION- M. PFISTER et al., Clinical Pharmacology & Therapeutics, (20090505), vol. 85, pages 513 - 519, XP009146835-
OPPOSITION- "Prandimet® (repaglinide and metformin HCI) Tablets", (20100500), pages 1 - 15, XP055591797-
OPPOSITION- "Sodium Starch Glycolate", Handbook of Pharmaceutical Excipients, (20060000), pages 701 - 704, XP002694443-
OPPOSITION- Terri L. ET AL, "NEW DRUGS IN DEVELOPMENT FOR THE THE TREATMENT OF DIABETES", Diabetes Spectrum, (20090000), vol. 22, no. 2, pages 92 - 106, XP009123031-
OPPOSITION- "View of NCT01002807 on 2009_10_26", ClinicalTrials.gov, (20150729), pages 1 - 3, XP002663638-
OPPOSITION- "View of NCT01002807 on 2009_10_26", ClinicalTrials.gov archive, (20091026), XP002663638-
OPPOSITION- V. KUKKAR et al., "Mixing and formulation of low dose drugs: underlying problems and solutions", Thai J. Pharm. Sci., (20080000), vol. 32, pages 43 - 58, XP055012249-
OPPOSITION- U. MANDAL et al., "Formulation and In Vitro Studies of a Fixed-Dose Combination of a Bilayer Matrix Tablet Containing Metformin HCl as Sustained Release and Glipizide as Immediate Release", Drug Development and Industrial Pharmacy, (20080000), vol. 34, pages 305 - 313, XP055585729
OPPOSITION- Debra S. hausman, "COMPARISON OF LOW SHEAR, HIGH SHEAR, AND FLUID BED GRANULATION DURING LOW DOSE TABLET PROCESS DEVELOPMENT", DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY@, (20040000), vol. 30, no. 3, pages 259 - 266, XP009050681
OPPOSITION- C. J. BAILEY et al., "Fixed-dose single tablet antidiabetic combinations, review article", Diabetes, Obesity and Metabolism, (20090000), vol. 11, pages 527 - 533, XP055588773
OPPOSITION- "Fixed-dose single tablet antidiabetic combinations", Diabetes , Obesity and Metabolism, (20090000), vol. 11, pages 527 - 533, XP055588773
OPPOSITION- S. A. JABBOUR et al., "Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes, review article", Int. J. Clin. Practice, (20080000), vol. 62, no. 8, pages 1279 - 1284, XP055402102
OPPOSITION- "sodium glucose cotransport inhibition with dapagliflozin in type 2 diabes", Diabetes Care, (20090400), vol. 32, no. 4, pages 650 - 657, XP055012106

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents